SIX WEEKS OF SOFOSBUVIR/ LEDIPASVIR (SOF/LDV) ARE SUFFICIENT TO TREAT ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: THE HEPNET ACUTE HCV IV STUDY

被引：5
|
作者：
Deterding, K. [1 ]
Spinner, C. [2 ]
Schott, E. [3 ]
Welzel, T. [4 ]
Gerken, G. [5 ]
Klinker, H. [6 ]
Spengler, U. [7 ]
Wiegand, J. [8 ]
zur Wiesch, J. Schulze [9 ]
Pathil, A. [10 ]
Cornberg, M. [1 ,11 ,12 ]
Umgelter, A. [2 ]
Zoellner, C. [3 ]
Zeuzem, S. [4 ]
von der Leyen, H. [13 ]
von Witzendorff, D. [11 ]
Manns, M. P. [1 ,11 ,12 ]
Wedemeyer, H. [1 ,11 ,12 ]
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Hosp Klinikum Rechts Isar, Munich, Germany
[3] Charite Univ Med Berlin, Berlin, Germany
[4] Univ Hosp Frankfurt, Frankfurt, Germany
[5] Univ Hosp Essen, Essen, Germany
[6] Univ Wurzburg, Med Ctr, Wurzburg, Germany
[7] Univ Hosp Bonn, Bonn, Germany
[8] Univ Leipzig, Leipzig, Germany
[9] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[10] Univ Clin Heidelberg, Heidelberg, Germany
[11] German Liver Fdn, HepNet Study House, Hannover, Germany
[12] German Liver Fdn, German Ctr Infect Res, HepNet Study House, Hannover, Germany
[13] Hannover Clin Trial Ctr GmbH, Hannover, Germany
来源：
JOURNAL OF HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
10.1016/S0168-8278(16)00177-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LBO8
引用
收藏
页码：S211 / S211
页数：1
相关论文
共 50 条
  • [1] Six weeks of sofosbuvir/ledipasvir treatment of acute hepatitis C virus genotype 1 monoinfection: Final results of the The German HepNet Acute HCV IV Study
    Deterding, Katja
    Spinner, Christoph D.
    Schott, Eckart
    Welzel, Tania M.
    Gerken, Guido
    Klinker, Hartwig H.
    Spengler, Ulrich
    Wiegand, Johannes
    zur Wiesch, Julian Schulze
    Pathil, Anita
    Cornberg, Markus
    Umgelter, Andreas
    Zollner, Caroline
    Zeuzem, Stefan
    Papkalla, Armin
    Weber, Kristina
    Hardtke, Svenja
    von der Leyen, Heiko
    Koch, Armin
    von Witzendorff, Dorothee
    Manns, Michael P.
    Wedemeyer, Heiner
    [J]. HEPATOLOGY, 2016, 64 : 416A - 417A
  • [2] Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
    Deterding, Katja
    Spinner, Christoph D.
    Schott, Eckart
    Welzel, Tania M.
    Gerken, Guido
    Klinker, Hartwig
    Spengler, Ulrich
    Wiegand, Johannes
    zur Wiesch, Julian Schulze
    Pathil, Anita
    Cornberg, Markus
    Umgelter, Andreas
    Zoellner, Caroline
    Zeuzem, Stefan
    Papkalla, Armin
    Weber, Kristina
    Hardtke, Svenja
    von der Leyen, Heiko
    Koch, Armin
    von Witzendorff, Dorothee
    Manns, Michael P.
    Wedemeyer, Heiner
    [J]. LANCET INFECTIOUS DISEASES, 2017, 17 (02): : 215 - 222
  • [3] Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)
    Ashley N. Brown
    Lin Liu
    Jaime L. Rodriquez
    Lisa Zhao
    Layla Schuster
    Eric Li
    Gary P. Wang
    Michael N. Neely
    Walter Yamada
    George L. Drusano
    [J]. Scientific Reports, 7
  • [4] Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV)
    Brown, Ashley N.
    Liu, Lin
    Rodriquez, Jaime L.
    Zhao, Lisa
    Schuster, Layla
    Li, Eric
    Wang, Gary P.
    Neely, Michael N.
    Yamada, Walter
    Drusano, George L.
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [5] Real-World Retreatment of Sofosbuvir/Ledipasvir (SOF/LDV) Failures In Hepatitis C Virus Genotype 1 infection
    Pearlman, Brian
    Hinds, Andrew
    Perrys, Michael
    [J]. HEPATOLOGY, 2016, 64 : 478A - 478A
  • [6] LEDIPASVIR (LDV)/SOFOSBUVIR (SOF) TREATMENT OF HEPATITIS C VIRUS (HCV) IS ASSOCIATED WITH REDUCTION OF SERUM APOLIPOPROTEIN LEVELS
    Younossi, Z.
    Elsheikh, E.
    Stepanova, M.
    Gerber, L.
    Nader, F.
    Brainard, D.
    McHutchinson, J. G.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S599 - S599
  • [7] Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure
    Hatanaka, Takeshi
    Naganuma, Atsushi
    Tateyama, Yumeo
    Yoshinari, Fukiko
    Hoshino, Takashi
    Sato, Ken
    Hmwe, Su Su
    Aizaki, Hideki
    Wakita, Takaji
    Kakizaki, Satoru
    Uraoka, Toshio
    [J]. INTERNAL MEDICINE, 2019, 58 (20) : 2969 - 2975
  • [8] Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study
    Maasoumy, Benjamin
    Ingiliz, Patrick
    Spinner, Christoph D.
    Cordes, Christiane
    Stellbrink, Hans-Juergen
    zur Wiesch, Julian Schulze
    Schneeweiss, Stephan M.
    Deterding, Katja
    Mueller, Tobias
    Kahlhoefer, Julia
    Doerge, Petra
    von Karpowitz, Maria
    Manns, Michael P.
    Wedemeyer, Heiner
    Cornberg, Markus
    [J]. JHEP REPORTS, 2023, 5 (03)
  • [9] A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection
    Li, Chen
    Hu, JinHua
    [J]. MEDICINE, 2018, 97 (15)
  • [10] LONG-TERM OUTCOMES OF LEDIPASVIR/SOFOSBUVIR (LDV/ SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (HCV) GENOTYPE 1 PATIENTS IN THE UK
    Guerra, I
    Marie, L.
    Cure, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A675 - A675
12345